Guillain-Barré Syndrome
An acute autoimmune nerve disorder triggered by a recent infection, causing rapidly worsening, ascending muscle weakness and loss of reflexes.
Emergency Management: Rapid onset of neuromuscular respiratory failure; severe autonomic storming resulting in hemodynamic collapse.
Guillain-Barré Syndrome (GBS) is an acute, immune-mediated, rapidly progressive polyradiculoneuropathy. It is characterized by symmetric ascending muscle weakness and areflexia, typically developing over days to up to four weeks. The immune system mistakenly attacks the peripheral nervous system (myelin sheath or axons), most commonly following a preceding gastrointestinal or respiratory infection.
Detailed Overview
GBS is a neurologic emergency because up to 30% of patients will develop respiratory muscle failure requiring mechanical ventilation, and autonomic dysfunction can cause lethal arrhythmias. The most common subtype in North America and Europe is Acute Inflammatory Demyelinating Polyneuropathy (AIDP). Axonal variants (AMAN, AMSAN) are more common in Asia and generally portend a slower recovery. Rapid diagnosis based on clinical presentation, supported by lumbar puncture and electromyography, is critical to initiate immunomodulatory therapy (IVIG or plasmapheresis) and alter the natural course of the disease.
Epidemiology & Demographics
Annual incidence is 1-2 per 100,000 globally. Affects all age groups, but incidence increases by 20% with every 10-year increase in age. Males are affected slightly more often than females (1.5:1).
Etiological Mechanism
Considered an autoimmune disease triggered by molecular mimicry. About two-thirds of cases are preceded by an infectious illness 1-6 weeks prior to the onset of neurologic symptoms. Campylobacter jejuni is the most common identified infectious trigger (associated with severe axonal variants and anti-GM1 antibodies). Other triggers include Cytomegalovirus, Epstein-Barr virus, Mycoplasma pneumoniae, and Zika virus.
Primary Causes
Post-infectious molecular mimicry (Campylobacter jejuni, CMV, Zika). Extremely rare instances associated with vaccinations (e.g., 1976 Swine Flu vaccine), though the background risk of GBS is much higher from influenza infection itself.
Pathogenesis is driven by molecular mimicry. Lipooligosaccharides on the surface of infectious agents (like C. jejuni) structurally resemble gangliosides (e.g., GM1, GD1a) found on peripheral nerve myelin or the axonal axolemma. The immune system generates antibodies against the pathogen, which cross-react with the peripheral nerve gangliosides. This binding activates the complement cascade (MAC complex formation) and recruits macrophages. In AIDP, macrophages strip the myelin sheath, causing conduction block and flaccid weakness. In axonal forms (AMAN), the attack is directly against the axon nodes of Ranvier, leading to severe axonal degeneration.
Diagnostic Criteria & Guidelines
Clinical diagnosis based on progressive symmetric weakness and areflexia. Supported by cerebrospinal fluid (CSF) analysis showing albuminocytologic dissociation and Nerve Conduction Studies (NCS) showing demyelination or axonal loss.
Intravenous Immunoglobulin (IVIG) 0.4 g/kg/day for 5 days OR Plasma Exchange (Plasmapheresis) 4-6 exchanges over 7-10 days. Both are equally effective; they should not be combined. Treatment should be initiated as soon as possible, ideally within 2 weeks of symptom onset. Corticosteroids are explicitly NOT effective and should be avoided.
Second-Line & Adjunctive Therapy
Supportive care in ICU setting is the cornerstone. Aggressive physical and occupational therapy once the patient is stable.
Surgical & Procedural Management
Tracheostomy may be required for patients with prolonged respiratory failure to facilitate weaning from the ventilator. Percutaneous Endoscopic Gastrostomy (PEG) for severe bulbar dysfunction.
Patient Counseling & Advice
Recovery is a marathon, not a sprint. 80% of patients recover walking independently, but it can take 6-12 months, and mild residual deficits (like foot drop or fatigue) are common. The risk of recurrence is very low (about 2-5%).
Follow-Up & Monitoring Schedule
During acute phase: Monitor Forced Vital Capacity (FVC) and Negative Inspiratory Force (NIF) every 4 hours. Intubate if FVC < 20 mL/kg or NIF drops below -30 cm H2O. Continuous telemetry monitoring for arrhythmias.
Preventive Strategies
No specific prevention. Practice safe food handling (C. jejuni is often foodborne via undercooked poultry) and general hand hygiene.
Mortality is 3-7% (mostly from autonomic dysfunction, pneumonia, or pulmonary embolism). Around 20% remain with significant disability at 1 year. Most have full or near-full functional recovery.